FFO
CRDF icon

Fortitude Family Office’s Cardiff Oncology CRDF Stock Holding History

Fortitude Family Office’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493 Buy
+379
New +$602 ﹤0.01% 1984

Other funds holding CRDF

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
CAWM
Capital Advisors Wealth Management Yakima, Washington $851M AUM 22.16% 1-Year Est. Return
SA
Scarborough Advisors Annapolis, Maryland $871M AUM 21.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

Fortitude Family Office's CRDF Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 379 shares worth $493. The stake represents ﹤0.01% of the portfolio and ranks #1984 among its holdings.

20 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Fortitude Family Office held 379 shares of Cardiff Oncology worth $493 as of Q2 2026.
  • Cardiff Oncology was a new Fortitude Family Office position in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1984 holding.
  • 20 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.